Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

Adding Coronary CT Angiography to Annual Firefighter Physicals Could Save Lives

News Conference News SCCT 2025

Adding Coronary CT Angiography to Annual Firefighter Physicals Could Save Lives

Yael L. Maxwell

July 18, 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

April 10, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

November 14, 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

AV Block Common After Transcatheter Tricuspid Valve Replacement for TR

News Conference News NY Valves 2024

AV Block Common After Transcatheter Tricuspid Valve Replacement for TR

Michael O'Riordan

June 07, 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

March 27, 2024

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

November 17, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.